{"id":4284,"date":"2010-11-02T05:56:55","date_gmt":"2010-11-02T09:56:55","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?p=4284"},"modified":"2011-07-19T17:44:44","modified_gmt":"2011-07-19T21:44:44","slug":"is-dabigatran-more-cost-effective-than-warfarin-in-af","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2010\/11\/02\/is-dabigatran-more-cost-effective-than-warfarin-in-af\/","title":{"rendered":"Is Dabigatran More Cost-Effective Than Warfarin in AF?"},"content":{"rendered":"<div>\n<p>Dabigatran, newly approved by the FDA to prevent stroke in patients with atrial fibrillation (AF), might turn out to be a cost-effective alternative to warfarin, according to an <a href=\"http:\/\/www.annals.org\/content\/early\/2010\/11\/01\/0003-4819-154-1-201101040-00289.full\"><em>Annals of Internal Medicine<\/em> study<\/a>.\u00a0Using data from\u00a0<a href=\"http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa0905561\">the RE-LY trial<\/a>, James Freeman and colleagues modeled the quality-adjusted survival and cost-effectiveness of dabigatran compared with high- or low-dose warfarin among adults older than 65 with AF. Cost was estimated based on current pricing in the U.K., where dabigatran has been approved since 2008.<\/p>\n<p>The researchers found that high-dose dabigatran was the most efficacious and cost-effective strategy. Depending on pricing in the U.S., they conclude, the new drug might prove to be a more cost-effective option than warfarin.\u00a0(Last week, <a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/dabigatran-to-cost-237-per-month-at-the-drugstore\/\">CardioExchange reported <\/a>that dabigatran will cost about $237\/month at U.S. pharmacies.)<\/p>\n<p><em>Comments are closed on this post, but please join the conversation at our <a href=\"..\/dabigatran-resource-round-up\/\">Dabigatran Resource Round-Up<\/a>.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dabigatran, newly approved by the FDA to prevent stroke in patients with atrial fibrillation (AF), might turn out to be a cost-effective alternative to warfarin, according to an Annals of Internal Medicine study.\u00a0Using data from\u00a0the RE-LY trial, James Freeman and colleagues modeled the quality-adjusted survival and cost-effectiveness of dabigatran compared with high- or low-dose warfarin [&hellip;]<\/p>\n","protected":false},"author":577,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[495,13,1,7],"tags":[492,516,339,368],"class_list":["post-4284","post","type-post","status-publish","format-standard","hentry","category-anticoagulation-2","category-electrophysiology","category-general","category-prevention","tag-anticoagulation","tag-cost-effectiveness","tag-dabigatran","tag-warfarin"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/4284","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/577"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=4284"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/4284\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=4284"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=4284"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=4284"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}